Oncotarget

Reviews:

Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target

Yiping Wen _, Jing Cai, Yaya Hou, Zaiju Huang & Zehua Wang

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:37974-37990. https://doi.org/10.18632/oncotarget.16467

Metrics: PDF 1030 views  |   HTML 1755 views  |   ?  


Abstract

Yiping Wen1,*, Jing Cai1,*, Yaya Hou1, Zaiju Huang1 and Zehua Wang1

1 Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

* These authors have contributed equally to this work

Correspondence to:

Zehua Wang, email:

Keywords: EZH2, cancer stem cells, sphere, histone lysine methylation, polycomb repressive complex

Received: November 02, 2016 Accepted: March 02, 2017 Published: March 22, 2017

Abstract

Epigenetic modifications in cancer stem cells largely result in phenotypic and functional heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly expressed in cancer stem cells of numerous malignant tumors and has a critical function in cancer stem cell expansion and maintenance. Here, we review up-to-date information regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem cells in various malignant tumors and discuss the therapeutic potential of targeting EZH2 in tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16467